This vaccination series is believed to be able to prevent
more than 12,000 cases of meningitis and bacteremia, 53,000
cases of pneumonia, 1 million episodes of otitis media, and
116 deaths due to pneumococcal infection.
Before accounting for vaccine costs, this program could save
$342 million in medical and $415 million in work loss and
other costs from averted pneumococcal disease.
Vaccination of healthy infants would result in net savings
for society if the vaccine costs less than $46 per dose and
net savings for the health care payer (i.e. HMO) if the vaccine
costs less than $18 per dose.
Currently, at the manufacturer's list price ($58 per dose),
the program would cost society $80,000 per life-year saved
or $160 per otitis media episode prevented or $3200 per pneumonia
case prevented, $15,000 for bacteremia prevented and
$280,000 for meningitis episode prevented.
At its current listed price, the vaccine is not cost-effective
but has the potential to be.